Triple
T9812320
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | aflibercept |
E238303
|
entity |
| Predicate | usedWith |
P4791
|
FINISHED |
| Object |
irinotecan
Irinotecan is a chemotherapy drug, specifically a topoisomerase I inhibitor, commonly used to treat colorectal and other cancers.
|
E823218
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: irinotecan | Statement: [aflibercept, usedWith, irinotecan]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: irinotecan Context triple: [aflibercept, usedWith, irinotecan]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
C.
docetaxel
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
D.
vincristine
Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
-
E.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: irinotecan Triple: [aflibercept, usedWith, irinotecan]
Generated description
Irinotecan is a chemotherapy drug, specifically a topoisomerase I inhibitor, commonly used to treat colorectal and other cancers.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: irinotecan Target entity description: Irinotecan is a chemotherapy drug, specifically a topoisomerase I inhibitor, commonly used to treat colorectal and other cancers.
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
C.
docetaxel
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
D.
vincristine
Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
-
E.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ca84defac48190abc1148804f184c1 |
completed | March 30, 2026, 2:12 p.m. |
| NER | Named-entity recognition | batch_69cdb222ba788190a9085272a3de7852 |
completed | April 2, 2026, 12:02 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d1cc63c450819091e57030a48e7d88 |
completed | April 5, 2026, 2:43 a.m. |
| NEDg | Description generation | batch_69d1cce3d9d481909eaf7278dfe20955 |
completed | April 5, 2026, 2:45 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69d1cd5d1670819085c58ff8889318af |
completed | April 5, 2026, 2:47 a.m. |
Created at: March 30, 2026, 8:30 p.m.